Conducting preclinical animal studies pose a number of challenges for biopharmaceutical companies including the need for costly vivarium space, having the necessary expertise, and ensuring regulatory compliance. Charles River Labs’ CRADL, the Charles River Accelerator and Development Lab, offers companies an alternative to building and staffing their own vivaria with state-of-the-art facilities located in major biotech centers. CRADL provides scalable and flexible solutions that can save young companies the need for substantial capital expenditures on space, equipment, and staff. We spoke to Julie Freebersyser, senior director of CRADL, about the company’s offerings, its expansion through its 2022 acquisition of Explora BioLabs, and how companies working with CRADL are able to leverage the greater expertise and services within Charles River.
